Annals of Nuclear Medicine

, Volume 17, Issue 3, pp 205–211

Preclinical studies on [11C]TMSX for mapping adenosine A2A receptors by positron emission tomography

  • Kiichi Ishiwata
  • Wei-Fang Wang
  • Yuichi Kimura
  • Kazunori Kawamura
  • Kenji Ishii
Original Article

DOI: 10.1007/BF02990023

Cite this article as:
Ishiwata, K., Wang, W., Kimura, Y. et al. Ann Nucl Med (2003) 17: 205. doi:10.1007/BF02990023

Abstract

In previousin vivo studies with mice, rats and monkeys, we have demonstrated that [11C]TMSX ([7-methyl-11C]-(E)-8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine) is a potential radioligang for mapping adenosine A2A receptors of the brain by positron emission tomography (PET). In the present study, we performed a preclinical study. A suitable preparation method for [11C]TMSX injection was established. The radiation absorbed-dose by [11C]TMSX in humans estimated from the tissue distribution in mice was low enough for clinical use, and the acute toxicity and mutagenicity of TMSX were not found. The striatal uptake of [11C]TMSX in mice was reduced by pretreatment with theophylline at the dose of 10 and 100mg/kg, suggesting that the [11C]TMSX PET should be carefully performed in the patients received with theophylline. We have concluded that [11C]TMSX is suitable for mapping adenosine A2A receptors in the human brain by PET.

Key words

Adenosine A2A receptor[11C]TMSXcentral nervous systempositron emission tomography

Copyright information

© Springer 2003

Authors and Affiliations

  • Kiichi Ishiwata
    • 1
  • Wei-Fang Wang
    • 1
  • Yuichi Kimura
    • 1
  • Kazunori Kawamura
    • 1
  • Kenji Ishii
    • 1
  1. 1.Positron Medical CenterTokyo Metropolitan Institute of GerontologyTokyoJapan